

WHAT IS CLAIMED IS:

1. A pharmaceutical composition for the prevention or treatment of soft tissue cancer in mammals comprising a pharmaceutically effective amount of at least one plant essential oil compound and at least one signal transduction modulator.
- 5 2. The pharmaceutical composition of claim 1, wherein the plant essential oil compound is selected from the group consisting of ~~aldehyde C16 (pure), amyl cinnamic aldehyde, amyl salicylate, anisic aldehyde, benzyl alcohol, benzyl acetate, cinnamaldehyde, cinnamic alcohol, α -terpineol, carvacrol, carveol, citral, citronellal, citronellol, p-cymene, diethyl phthalate, dimethyl salicylate, dipropylene glycol, eucalyptol (cineole), eugenol, iso-eugenol, galaxolide, geraniol, guaiacol, ionone, d-limonene, menthol, methyl anthranilate, methyl ionone, methyl salicylate, α -phellandrene, pennyroyal oil, perillaldehyde, 1- or 2-phenyl ethyl alcohol, 1- or 2-phenyl ethyl propionate, piperonal, piperonyl acetate, piperonyl alcohol, D-pulegone, terpinen-4-ol, terpinyl acetate, 4-tert butylcyclohexyl acetate, thyme oil, thymol, metabolites of trans-anethole, vanillin, and ethyl vanillin.~~
- 10 3. The pharmaceutical composition of claim 1, wherein the signal transduction modulator is selected from the group consisting of cyclic adenosine monophosphate (cAMP) / cAMP-dependent protein kinase, tyrosine kinase, calcium phospholipid-dependent protein kinase (PKC), mitogen activated protein kinase family members, calcium-calmodulin-dependent protein kinase, and growth factor receptor inhibitors.
- 15 4. The pharmaceutical composition of claim 1, further comprising a pharmaceutically acceptable carrier.
- 20 5. The pharmaceutical composition of claim 1, wherein the soft tissue cancer is breast cancer.
- 25 6. The pharmaceutical composition of claim 2, wherein the plant essential oil compound is eugenol.
7. The pharmaceutical composition of claim 2, wherein the plant essential oil compound is thymol.
- 30 8. The pharmaceutical composition of claim 2, wherein the plant essential oil compound is isoeugenol.
9. The pharmaceutical composition of claim 2, wherein the plant essential oil compound is benzyl alcohol.
10. The pharmaceutical composition of claim 2, wherein the plant essential oil compound is carvacrol.

11. The pharmaceutical composition of claim 2, wherein the plant essential oil compound is cinnamic alcohol.

12. The pharmaceutical composition of claim 2, wherein the plant essential oil compound is cinnamic aldehyde.

5 13. The pharmaceutical composition of claim 2, wherein the plant essential oil compound is citronellal.

14. The pharmaceutical composition of claim 2, wherein the plant essential oil compound is trans-anethole.

10 15. A method for treating cancer, comprising administering to a patient in need thereof a therapeutically effective amount of the composition of claim 1.